立体定向放射外科联合活跃全身药物治疗的黑色素瘤脑转移患者生存分析
本研究纳入2010至2015年接受立体定向放射外科(SRS)治疗的108例黑色素瘤脑转移患者,分析总生存(OS)与颅内控制(BC)及其相关因素。73.1%患者在SRS前后6周内接受全身治疗;抗PD1组中位OS为20.4个月(95%CI 8.8–N/A),抗CTLA4组为7.5个月(95%CI 4.4–15.6),BRAF抑制剂±MEK抑制剂组为17.8个月(95%CI 11.8–N/A)。多因素分析显示年龄与全身治疗类型与OS强相关,年龄、ECOG体力状况、GPA评分及症状与BC相关。
要点
- 108例黑色素瘤脑转移患者接受SRS,73.1%接受全身治疗,中位随访8.6个月
- 抗PD1组中位OS 20.4个月,抗CTLA4组7.5个月,BRAFi±MEKi组17.8个月
- 年龄与全身治疗类型与OS强相关,年龄、ECOG评分、GPA评分及症状与BC相关
核心结论
- SRS联合全身治疗的患者结局良好,抗PD1治疗者生存最佳;年龄、体力状况与GPA评分等已知独立预后因素在该情形下仍然相关。
研究设计与样本
- 单中心(原文未报告中心数)队列研究,纳入2010至2015年接受SRS治疗的108例黑色素瘤脑转移患者,记录SRS前后6周内全身治疗使用情况。
主要发现
- 中位年龄64.3岁,中位随访8.6个月,79例(73.1%)接受全身治疗。
- 中位OS:抗CTLA4组7.5个月(95%CI 4.4–15.6),抗PD1组20.4个月(95%CI 8.8–N/A),BRAFi±MEKi组17.8个月(95%CI 11.8–N/A)。
- 中位BC:抗CTLA4组7.5个月(95%CI 4.0–15.6),抗PD1组12.7个月(95%CI 5.5–N/A),BRAFi±MEKi组12.7个月(95%CI 8.3–18.5)。
- 多因素分析中年龄与全身治疗类型与OS强相关;年龄、ECOG体力状况、GPA评分及症状与BC相关。
关键数值与推荐
- OS定义为自SRS至死亡或末次随访的时间,BC定义为随访期间无任何活动性颅内病变。
- 采用单因素与多因素Cox比例风险模型分析临床病理预后特征与OS、BC的关联。
临床怎么用
- 原文未据此给出推荐;结果显示SRS联合全身治疗(尤其抗PD1)患者生存最佳,年龄、体力状况与GPA评分仍具预后相关性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: With new systemic therapies demonstrating activity in melanoma brain metastasis, most of the previously reported stereotactic radiosurgery (SRS) data are superseded. In this study, we report the outcomes (overall survival [OS] and brain control [BC]) and identify factors that associate with such outcomes in the era of modern systemic therapy. METHOD: A total of 108 patients treated with SRS from 2010 to 2015 were included. Systemic treatment use within 6 weeks of SRS was noted. OS was defined as time from SRS to death or last follow-up, and BC was defined as absence of any active intracranial disease during follow-up. Univariate and multivariate Cox proportional hazard analyses were performed on clinico-pathological prognostic features associated with OS and BC. RESULTS: The median age was 64.3 years, and the median follow-up was 8.6 months. Seventy-nine (73.1%) patients received systemic treatment. The median OS were as follows: anti-CTLA4 - 7.5 months (95% CI: 4.4-15.6), anti-PD1 - 20.4 months (95% CI: 8.8 - N/A) and BRAF inhibitor (BRAFi) ± MEK inhibitor (MEKi) - 17.8 months (95% CI: 11.8 - N/A). Median BC was as follows: anti-CTLA4 - 7.5 months (95% CI: 4.0-15.6), anti-PD1 - 12.7 months (95% CI: 5.5 - N/A) and BRAFi ± MEKi - 12.7 months (95% CI: 8.3-18.5). In multivariate analysis, age and type of systemic therapy were strongly associated with OS. Age, Eastern Cooperative Oncology Group performance status, Graded Prognostic Assessment (GPA) score, and presence of symptoms were associated with BC. CONCLUSIONS: Favourable outcomes are seen in patients treated with SRS and with the best survival seen in patients treated with anti-PD1. Known independent prognostic factors for survival such as age and performance status and GPA score remain relevant in this setting.
引用
- Choong ES, Lo S, Drummond M, et al. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer. 2017. PMID: 28236768. doi:10.1016/j.ejca.2017.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。